MeiraGTx Holdings plc (MGTX): Total Liabilities
$250.22M
As of 2025-12-31
$180.67M
As of 2026-06-30
+7.7%
3-year compound annual growth
+14.9%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $250.22M | +23.9% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $201.92M | +7.1% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $188.57M | -6.0% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $200.50M | +48.8% | 2024-03-15, Balance as of period end |
| 2021-12-31 | $134.76M | +7.7% | 2023-03-14, Balance as of period end |
| 2020-12-31 | $125.14M | -6.0% | 2022-03-10, Balance as of period end |
| 2019-12-31 | $133.09M | +740.4% | 2021-03-11, Balance as of period end |
| 2018-12-31 | $15.84M | -27.6% | 2020-03-11, Balance as of period end |
| 2017-12-31 | $21.88M | n/a | 2019-03-26, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $250.22M | +23.9% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $61.05M | +22.6% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $410.94M | +15.6% |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $343.26M | -17.0% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $30.80M | -21.7% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $237.55M | -4.4% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $306.28M | -10.6% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $64.77M | -66.2% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $22.92M | -19.8% |
Compare MGTX, FDMT, AUTL, RXRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗